KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas
18 Marzo 2024 - 4:30AM
Business Wire
– Delays in treating attacks lead to increased
anxiety, quality of life issues, higher frequency of returning
attacks, and suboptimal clinical outcomes in both on-demand and
prophylaxis patients -
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage
pharmaceutical company focused on the discovery, development, and
commercialization of oral, small molecule protease inhibitors,
today announced that it presented multiple analyses of the
relationship between the time to attack treatment and the effects
delays in treatment have on clinical outcomes of people living with
hereditary angioedema (HAE) at the 2024 HAEi Regional Conference
Americas that took place in Panama City, Panama.
“These data show once again that people living with HAE still
face challenges in following established guidelines for treating
their attacks,” said Ben Palleiko, Chief Executive Officer of
KalVista. “Even short treatment delays can lead to worse clinical
outcomes, and despite efficacious on-demand treatments, the fact
that they need to be injected results in barriers which lead to
significant underuse and resultant overuse of long-term
prophylaxis. If approved, sebetralstat should enable improved
compliance with these guidelines, which has the potential to help
people with HAE to better control their disease with a lower
overall burden of treatment.“
The following presentations occurred at the 2024 HAEi Regional
Conference Americas:
- Relationship Between Time to On-demand Treatment and
Quality of Life During Hereditary Angioedema Attacks: Sandra
Christiansen, University of California San Diego, La Jolla, CA,
United States (Oral Presentation)
- Treatment delays are associated with lower QoL and poorer
general health during HAE attack, emphasizing the benefits of
compliance with HAE guidelines and greater awareness of the impact
of delayed treatment on QoL
- Characterizing the Negative Impact of Delayed On-Demand
Treatment of HAE Attacks: Ricardo Zwiener, Servicio de Alergia
e Inmunología Clínica, Hospital Universitario Austral, Pilar,
Buenos Aires, Argentina (Poster Presentation)
- The time to feeling in control of an HAE attack and time to
feeling fully recovered were shorter for patients treating HAE
attacks in <1 hour versus those who waited ≥1 hour
- Anxiety Associated with Refilling On-demand Therapy for HAE
Attacks Contributes to Treatment Delay and Non-Treatment: Anete
S. Grumach, Clinical Immunology, Faculdade de Medicina, Centro
Universitario FMABC, Santo Andre, Brazil (Poster Presentation)
- Anxiety associated with not being able to refill on-demand
treatment impacted treatment decisions, which contributed to
treatment delay or resulted in non-treatment of HAE attacks
- Treatment Patterns of Patients Requiring Redosing of an
On-demand Treatment After the Return of an HAE Attack: William
Lumry, Allergy and Asthma Research Associates, Dallas, Texas,
United States. (Poster Presentation)
- HAE attacks initially treated within 1 hour returned less
frequently compared with attacks treated at 1 hour or longer
- Anxiety Associated with On-Demand Treatment for Hereditary
Angioedema (HAE) Attacks: Maeve O’Connor, Allergy, Asthma,
& Immunology Relief of Charlotte, Charlotte, NC, United States
(Poster Presentation)
- Both adults and adolescents with HAE reported moderate to
extreme anxiety when anticipating use of parenteral on-demand
treatment, irrespective of use of on-demand only or on-demand plus
LTP
- Characteristics of Hereditary Angioedema Attacks Among
Long-Term Prophylaxis Users: Maeve O’Connor, Allergy, Asthma,
& Immunology Relief of Charlotte, Charlotte, NC, United States
(Poster Presentation)
- Among HAE patients who had treated a recent attack, the
location and duration of the most recent attacks were similar
between long-term prophylaxis (LTP) and on-demand only users
Links to all posters and presentations can be found on the
KalVista website under “Publications”.
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a pharmaceutical company
focused on the discovery, development, and commercialization of
oral, small molecule protease inhibitors for diseases with
significant unmet need. KalVista disclosed positive phase 3 data
for the KONFIDENT trial for its oral, on-demand therapy
sebetralstat in February 2024. The Company anticipates submitting a
new drug application to the U.S. FDA for sebetralstat in the first
half of 2024 and expects to file for approval in Europe and Japan
later in 2024. In addition, KalVista’s oral Factor XIIa inhibitor
program represents a new generation of therapies that may further
improve the treatment for people living with HAE and other
diseases.
For more information about KalVista, please visit
www.kalvista.com.
Forward-Looking Statements
This press release contains "forward-looking" statements within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: "anticipate,"
"intend," "plan," "goal," "seek," "believe," "project," "estimate,"
"expect," "strategy," "future," "likely," "may," "should," "will"
and similar references to future periods. These statements are
subject to numerous risks and uncertainties that could cause actual
results to differ materially from what we expect. Examples of
forward-looking statements include, among others, timing or
outcomes of communications with the FDA, our expectations about
safety and efficacy of our product candidates and timing of
clinical trials and their results, our ability to obtain regulatory
approvals for sebetralstat and other candidates in development, the
success of any efforts to commercialize sebetralstat, the ability
of sebetralstat and other candidates in development to treat HAE or
other diseases, and the future progress and potential success of
our oral Factor XIIa program. Further information on potential risk
factors that could affect our business and financial results are
detailed in our filings with the Securities and Exchange
Commission, including in our annual report on Form 10-K for the
year ended April 30, 2023, our quarterly reports on Form 10-Q, and
our other reports that we may make from time to time with the
Securities and Exchange Commission. We undertake no obligation to
publicly update any forward-looking statement, whether written or
oral, that may be made from time to time, whether as a result of
new information, future developments or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240318610099/en/
KalVista Pharmaceuticals, Inc. Jarrod Aldom Vice
President, Corporate Communications (201) 705-0254
jarrod.aldom@kalvista.com
Ryan Baker Head, Investor Relations (617) 771-5001
ryan.baker@kalvista.com
KalVista Pharmaceuticals (NASDAQ:KALV)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
KalVista Pharmaceuticals (NASDAQ:KALV)
Gráfica de Acción Histórica
De May 2023 a May 2024